References
- Bauerschmitz GJ, Guse K, Kanerva A, Menzel A, Herrmann I, Desmond RA, . Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol Ther 2006;14:164–74.
- Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nat Clin Pract Oncol 2007;4:101–17.
- Alemany R. A smart move against cancer for vaccinia virus. Lancet Oncol 2008;9:507–8.
- Prestwich R, Harrington K, Vile R, Melcher A. Immunotherapeutic potential of oncolytic virotherapy. Lancet Oncol 2008;9:610–2.